Celsion's ThermoDox® HEAT Study Findings Reviewed at the 2013 European Conference on Interventional Oncology (ECIO) in

    Celsion's ThermoDox® HEAT Study Findings Reviewed at the 2013 European
 Conference on Interventional Oncology (ECIO) in Budapest, Hungary on June 19
                                 and 20, 2013

Duration of RFA Procedure Correlates with Meaningful Clinical Benefit

PR Newswire

LAWRENCEVILLE, N.J., June 20, 2013

LAWRENCEVILLE, N.J., June 20, 2013 /PRNewswire/ --Celsion Corporation
(NASDAQ: CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR,
EBIR, 2013 ECIO Program Co-Chairman and the Director of the Division of
Diagnostic Imaging and Intervention at Pisa University School of Medicine in
Italy and Lead European Principal Investigator for the HEAT Study reviewed
the clinical trial results from the Company's Phase III HEAT Study including
findings from the HEAT Study post-hoc analysis at the 2013 European Conference
on Interventional Oncology, which is being held June 19-22, 2013 in Budapest,
Hungary. The emerging post-hoc findings suggest that the heating cycles can
be optimized to markedly improve radiofrequency ablation (RFA) when used with
ThermoDox®. The post-hoc data indicates that ThermoDox® may provide potential
for clinically relevant improved progression free survival (PFS) and Overall
Survival (OS) outcomes. Professor Lencioni made two presentations on
hepatocellular carcinoma (HCC) and related advances in interventional

  oProfessor Lencioni's first presentation, titled "New Interventional
    Oncology Approaches in HCC; An Update on Clinical Trials" was held on
    Wednesday, June 19, 2013 at 2:30 p.m. (local time) in Plenary Session:
    Open Issues in the Management of Liver Cancer. This presentation is part
    of a joint symposium of the ECIO and the International Liver Cancer
    Association (ILCA). This special event will be chaired by Professor
    Lencioni (2013 ECIO Program Co-Chairman) and Dr. Joseph Llovet (ILCA
  oHis second presentation, titled "Thermally Sensitive Doxorubicin Carriers"
    was held on Thursday, June 20, 2013 at 10:30 a.m. (local time) in Plenary
    Session: New Horizons in Interventional Oncology

"I am pleased to present this post-hoc analysis of a large subgroup of
patients from the Phase III HEAT Study to the European and international
interventional oncology community which may be indicating a meaningful
clinical benefit in both progression free survival (PFS) and overall survival
(OS) in patients who received an optimized RFA procedure," said Professor
Lencioni. "It is important to note the duration of heat from the RFA
procedure is a key factor in a successful clinical outcome when combined with
ThermoDox®. These findings are consistent with our understanding that
increased perfusion and associated heating time are important factors for
ensuring that the heat-sensitive liposomes are activated to deposit high
concentrations of doxorubicin in the tumor and the surrounding liver tissue."

The data from the HEAT Study post-hoc analysis presented by Professor Lencioni
demonstrate that ThermoDox® markedly improves PFS and OS in patients with a
single lesion if their lesions undergo RFA for 45 minutes or more. These
findings apply to HCC lesions regardless of size and represent a subgroup of
approximately 300 patients or 42% of the patients in the HEAT Study.

  oIn the patient subgroup treated in the ThermoDox® arm whose RFA procedure
    lasted longer than 45 minutes and was completed within 90 minutes (40% of
    single lesion patients) Overall Survival improved by 66% (Hazard Ratio of
    0.602) when compared to the control arm of RFA treatment only.
  oIn the patient subgroup treated in the ThermoDox® arm whose RFA procedure
    lasted longer than 90 minutes (23% of single lesion patients), Overall
    Survival almost doubled (Hazard Ratio of 0.508) when compared to the
    control arm of RFA treatment only.
  oWhen combined, these two subgroups show clinical results that indicated a
    53% improvement in Overall Survival, a Hazard Ratio of 0.65, and a
    P[value] = 0.105.
  oIn contrast, the patient subgroup treated with ThermoDox® whose RFA
    procedure lasted less than 45 minutes in duration (37% of single lesion
    patients) indicated that the control arm had an improved Overall Survival
    benefit when compared to the ThermoDox® arm.
  oThe Hazard Ratios reported above should be viewed with caution since they
    are not statistically significant and the HEAT Study has not reached its
    median point for Overall Survival analysis. Celsion will continue
    following all patients enrolled in the HEAT Study to the secondary
    endpoint, Overall Survival, and update its subgroup analysis based on RFA
    heating duration.

Professor Lencioni's presentation is available on the Company's website at
www.celsion.com under "News & Investor Info – Events & Presentations."

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative
cancer drugs, including tumor-targeting treatments using focused heat energy
in combination with heat-activated liposomal drug technology. Celsion has
research, license or commercialization agreements with leading institutions,
including the National Institutes of Health, Duke University Medical Center,
University of Hong Kong, the University of Pisa, the UCLA Department of
Medicine, the Kyungpook National University Hospital, the Beijing Cancer
Hospital and the University of Oxford. For more information on Celsion, visit
our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this
release are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and development
activities and in clinical trials; the significant expense, time, and risk of
failure of conducting clinical trials; HEAT Study data is subject to further
verification and review by the HEAT Study Data Management Committee; the need
for Celsion to evaluate its future development plans; termination of the
Technology Development Contract or collaboration between Celsion and HISUN at
any time; possible acquisitions or licenses of other technologies, assets or
businesses or the possible failure to make such acquisitions or licenses;
possible actions by customers, suppliers, competitors, regulatory authorities;
and other risks detailed from time to time in the Celsion 's periodic reports
and prospectuses filed with the Securities and Exchange Commission. Celsion
assumes no obligation to update or supplement forward-looking statements that
become untrue because of subsequent events, new information or otherwise.

Investor Contact
Jeffrey W. Church
Sr. Vice President — Corporate
Strategy and Investor Relations

SOURCE Celsion Corporation

Website: http://www.celsion.com
Press spacebar to pause and continue. Press esc to stop.